Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 64.1% in March

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 68,800 shares, a decrease of 64.1% from the February 28th total of 191,900 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average daily volume of 1,220,000 shares, the short-interest ratio is presently 0.1 days.

Vincerx Pharma Price Performance

NASDAQ VINC opened at $0.60 on Thursday. The stock has a market capitalization of $1.35 million, a P/E ratio of -0.03 and a beta of 1.43. The business has a 50 day simple moving average of $1.32 and a 200 day simple moving average of $5.37. Vincerx Pharma has a one year low of $0.49 and a one year high of $136.80.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.